Patient characteristics of the study group (36 patients)
Parameter . | No. (%) . |
|---|---|
| Age, 60 y or older | 8 (22) |
| Female sex | 21 (58) |
| Performance status | |
| 0 to 1 | 35 (97) |
| 2 | 1 (3) |
| Splenomegaly | 1 (3) |
| Diagnosis to therapy, mo | |
| Fewer than 12 | 1 (3) |
| 12 to 35 | 24 (67) |
| 36 or more | 11 (31) |
| Hemoglobin level, g/dL | |
| Lower than 12 | 15 (42) |
| WBC count, × 109/L | |
| Lower than 10 | 25 (69) |
| 10 or higher | 11 (31) |
| Platelet count, × 109/L | |
| 450 or higher | 5 (14) |
| Peripheral basophils, 7% or higher | 1 (3) |
| Marrow basophils, 5% or higher | 1 (3) |
| Ph status before therapy | |
| 90% or less | 21* (58) |
| More than 90% | 15 (42) |
| Clonal evolution present | 4 (11) |
| Response to IFN-α | |
| Hematologic resistance | 1 (3) |
| Cytogenetic resistance | 6 (17) |
| Cytogenetic refractoriness | 6 (17) |
| IFN-α intolerance | 21 (58) |
Parameter . | No. (%) . |
|---|---|
| Age, 60 y or older | 8 (22) |
| Female sex | 21 (58) |
| Performance status | |
| 0 to 1 | 35 (97) |
| 2 | 1 (3) |
| Splenomegaly | 1 (3) |
| Diagnosis to therapy, mo | |
| Fewer than 12 | 1 (3) |
| 12 to 35 | 24 (67) |
| 36 or more | 11 (31) |
| Hemoglobin level, g/dL | |
| Lower than 12 | 15 (42) |
| WBC count, × 109/L | |
| Lower than 10 | 25 (69) |
| 10 or higher | 11 (31) |
| Platelet count, × 109/L | |
| 450 or higher | 5 (14) |
| Peripheral basophils, 7% or higher | 1 (3) |
| Marrow basophils, 5% or higher | 1 (3) |
| Ph status before therapy | |
| 90% or less | 21* (58) |
| More than 90% | 15 (42) |
| Clonal evolution present | 4 (11) |
| Response to IFN-α | |
| Hematologic resistance | 1 (3) |
| Cytogenetic resistance | 6 (17) |
| Cytogenetic refractoriness | 6 (17) |
| IFN-α intolerance | 21 (58) |
15 with IFN-α intolerance